You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 93 No. 5, MAY 1954 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

NITROGEN MUSTARD IN TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS

EDMUND L. DUBOIS, M.D.

AMA Arch Intern Med. 1954;93(5):667-672.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

CHASIS, Goldring, and Baldwin in 1949 reported on the favorable use of methyl-bis (β-chloroethyl) amine hydrochloride (nitrogen mustard) in glomerulonephritis.1 Their rationale for using this drug was based on "the assumption that human glomerulonephritis is the result of tissue alterations in the kidneys induced by an antigen-antibody complex."2 Nitrogen mustard is known to inhibit antibody production. Several confirmatory reports of the use of the agent in the nephrotic syndrome have appeared in the literature.* In a recent paper Baldwin, McLean, Chasis, and Goldring stated that the evidence favoring the use of nitrogen mustard in human glomerulonephritis is equivocal.2 Dustan, Corcoran, and Haserick first used this drug in systemic lupus erythematosus with renal involvement.5

Rohn and Bond administered nitrogen mustard to five patients who had systemic lupus erythematosus without renal damage. Three cases were benefited.6

Since Duston's preliminary report, in 1951, we have treated 20 patients with active acute and subacute . . . [Full Text PDF of this Article]


Author Affiliations

LOS ANGELES

From the Department of Internal Medicine, University of Southern California Medical School, and the Los Angeles County General Hospital.


Footnotes

Methyl-bis (β-chloroethyl) amine hydrochloride (Mustargen) was supplied by Dr. E. Alpert, of Merck & Company, Inc., Rahway, N. J. Triethylene melamine was provided by Dr. J. M. Ruegsegger, of Lederle Laboratories Division, American Cyanamid Company, Pearl River, N. Y.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1954 American Medical Association. All Rights Reserved.